Phase 2 Study to Evaluate Ofirnoflast (HT-6184) + Semaglutide Combination for Obese T2DM
A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
Abstract
A Phase 2 study is evaluating the efficacy and safety of oral ofirnoflast (HT-6184) combined with subcutaneous semaglutide in obese participants with Type 2 Diabetes Mellitus.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
